Stockscreener 앱 받기
8.98
4.91%
0.42
시간 외 거래:
8.99
0.010
+0.11%
4 D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st
4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus
RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart
4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5) - marketscreener.com
4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView
4D Molecular Therapeutics (FDMT) details retina and lung gene therapy pipeline in 10-K - Stock Titan
4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire
Biotech 4D Molecular Therapeutics lines up March investor conference talks - Stock Titan
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference - Yahoo Finance
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk - Yahoo Finance
FDMT: 4D-150's rapid phase III progress and broad commercialization plans highlight strong market potential - TradingView
FDMT: Rapid phase 3 progress and strong market interest position 4D-150 for global commercialization - TradingView
FDMT: 4D-150 shows strong efficacy and safety, with global phase III trials advancing ahead of schedule - TradingView
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
FDMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? - Finviz
FDMT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Chardan Capital maintains 4D Molecular Therapeutics (FDMT) buy recommendation - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%Time to Buy? - MarketBeat
Key Catalysts on the Horizon for 4D Molecular Therapeutics - AD HOC NEWS
4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Friday - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
Biotech 4DMT heads to three March healthcare investor conferences - Stock Titan
Novo Holdings A/S reports 6.4% passive stake in 4D MT (FDMT) - Stock Titan
4DMT Announces New Employment Inducement Grants - The Manila Times
Biotech 4DMT hands 124,200 stock units to just nine recruits - Stock Titan
4D Molecular Therapeutics Advances Toward Phase 3 Milestones in Retina Gene Therapy - AD HOC NEWS
Barclays flags M&A tailwinds and pricing relief as upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - MSN
Will 4D Molecular Therapeutics Inc. stock attract ESG investorsJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - mfd.ru
Will 4D Molecular Therapeutics Inc. benefit from geopolitical trends2025 Institutional Moves & Smart Allocation Stock Reports - mfd.ru
What are analysts’ price targets for 4D Molecular Therapeutics Inc.2025 Support & Resistance & Entry Point Strategy Guides - mfd.ru
4D Molecular (FDMT) Completes Enrollment for Key Phase 3 Wet AMD Trial - GuruFocus
What is 4D Molecular Therapeutics Inc. s debt to equity ratioEarnings Recap Summary & Reliable Price Breakout Alerts - mfd.ru
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - Yahoo Finance
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Finviz
Barclays Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight Recommendation - Nasdaq
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
4D Molecular Therapeutics Restructures Equity via Warrant Exchange - TipRanks
4D Molecular Therapeutics: A Valuation Disconnect Amidst Clinical Progress - AD HOC NEWS
4D Molecular (FDMT) Grants RSUs to New Employees - GuruFocus
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees - Intellectia AI
Biotech 4DMT hands 23,600 stock units to four new hires under award plan - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update - MarketBeat
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial potential in retinal disease - TradingView
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Intraday Action & Fast Moving Stock Trade Plans - ulpravda.ru
Is 4D Molecular Therapeutics Inc. stock a buy on dipsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
Why 4D Molecular Therapeutics Inc. stock appeals to dividend seekersMarket Weekly Review & Low Drawdown Investment Strategies - Улправда
Stock Report: Can 4D Molecular Therapeutics Inc. stock double in next 5 years2025 Analyst Calls & Daily Technical Stock Forecast Reports - ulpravda.ru
Smart Money: Is 4D Molecular Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Trade Ideas & Free Reliable Trade Execution Plans - Улправда
Will 4D Molecular Therapeutics Inc. stock gain from strong economyJuly 2025 Outlook & High Return Stock Watch Alerts - ulpravda.ru
Can 4D Molecular Therapeutics Inc. stock double in next 5 yearsJuly 2025 Institutional & Risk Controlled Swing Alerts - Улправда
1.20%
0.06%
자본화:
|
볼륨(24시간):